Literature DB >> 11949778

A systematic review of the use of atypical antipsychotics in autism.

L Barnard1, A H Young, J Pearson, J Geddes, G O'Brien.   

Abstract

Conventional antipsychotic medication is commonly prescribed to patients with autistic spectrum disorder. However, a high incidence of severe adverse reactions highlights the need to find more favourable treatments. Atypical antipsychotics may combine efficacy in ameliorating some autistic symptoms with a lower incidence of some adverse reactions. This article reviews the use of atypical antipsychotics in autistic disorder, with particular focus on behaviour, cognition and physical well-being. Thirteen studies using risperidone, three using olanzapine, one using clozapine, one using amisulpride and one using quetiapine were identified. Few firm conclusions can be drawn due to the limitations of the studies; however, there is an indication that risperidone may be effective in reducing hyperactivity, aggression and repetitive behaviours, often without inducing severe adverse reactions. Olanzapine and clozapine may also be effective; however, there is little evidence for using amisulpride or quetiapine in this population. Randomized trials are required to clarify the effectiveness of these agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11949778     DOI: 10.1177/026988110201600113

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  20 in total

1.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

2.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

3.  A Predictive Coding Account of Psychotic Symptoms in Autism Spectrum Disorder.

Authors:  Gerrit I van Schalkwyk; Fred R Volkmar; Philip R Corlett
Journal:  J Autism Dev Disord       Date:  2017-05

4.  Gadd45b knockout mice exhibit selective deficits in hippocampus-dependent long-term memory.

Authors:  Prescott T Leach; Shane G Poplawski; Justin W Kenney; Barbara Hoffman; Dan A Liebermann; Ted Abel; Thomas J Gould
Journal:  Learn Mem       Date:  2012-07-16       Impact factor: 2.460

5.  Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders.

Authors:  Helen H L Wong; Ronald G Smith
Journal:  J Autism Dev Disord       Date:  2006-10

6.  Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder.

Authors:  Johanna K Lake; Danica Denton; Yona Lunsky; Amy M Shui; Jeremy Veenstra-VanderWeele; Evdokia Anagnostou
Journal:  J Autism Dev Disord       Date:  2017-05

7.  Engaging Caregivers in the Treatment of Youth with Complex Developmental and Mental Health Needs.

Authors:  Ahrang Yoo; Monique Kim; Melissa M Ross; Angela Vaughn-Lee; Beverly Butler; Susan dosReis
Journal:  J Behav Health Serv Res       Date:  2018-07       Impact factor: 1.505

8.  Medicaid expenditures for children with autistic spectrum disorders: 1994 to 1999.

Authors:  David S Mandell; Jun Cao; Richard Ittenbach; Jennifer Pinto-Martin
Journal:  J Autism Dev Disord       Date:  2006-05

Review 9.  Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents.

Authors:  Lesley J Scott; Sohita Dhillon
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

10.  Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Authors:  Yong Kee Choi; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2008-10-09       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.